An Open-label Phase II Study of Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy - RESOUND
Phase of Trial: Phase II
Latest Information Update: 21 Feb 2018
At a glance
- Drugs Regorafenib (Primary)
- Indications Malignant melanoma; Ovarian cancer; Pancreatic cancer; Sarcoma
- Focus Therapeutic Use
- Acronyms RESOUND
- 11 Oct 2016 Results (n=20) from pancreatic cohort of the study presented at the 41st European Society for Medical Oncology Congress.
- 20 Jan 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 09 Dec 2014 New trial record